IN2014CN00572A - - Google Patents
Info
- Publication number
- IN2014CN00572A IN2014CN00572A IN572CHN2014A IN2014CN00572A IN 2014CN00572 A IN2014CN00572 A IN 2014CN00572A IN 572CHN2014 A IN572CHN2014 A IN 572CHN2014A IN 2014CN00572 A IN2014CN00572 A IN 2014CN00572A
- Authority
- IN
- India
- Prior art keywords
- compounds
- infections
- salts
- treating
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161525440P | 2011-08-19 | 2011-08-19 | |
| US201261650681P | 2012-05-23 | 2012-05-23 | |
| PCT/US2012/050268 WO2013028371A1 (en) | 2011-08-19 | 2012-08-10 | Benzofuran compounds for the treatment of hepatitis c virus infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN00572A true IN2014CN00572A (enEXAMPLES) | 2015-04-03 |
Family
ID=47746761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN572CHN2014 IN2014CN00572A (enEXAMPLES) | 2011-08-19 | 2012-08-10 |
Country Status (38)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103929965B (zh) * | 2011-08-17 | 2016-08-17 | 葛兰素史克有限责任公司 | 治疗方法 |
| HUE030300T2 (en) | 2011-08-19 | 2017-04-28 | Glaxo Group Ltd | Benzofuran compounds for the treatment of hepatitis c virus infections |
| BR112017009503A2 (pt) * | 2014-11-10 | 2018-02-06 | Glaxosmithkline Ip No 2 Ltd | composição farmacêutica parenteral de ação prolongada, métodos para tratar, para prevenir e para curar uma infecção por hcv, e, kit. |
| KR20170081257A (ko) * | 2014-11-10 | 2017-07-11 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | C형 간염에 대한 조합 장기 작용 조성물 및 방법 |
| KR20180006522A (ko) | 2016-07-07 | 2018-01-18 | 삼성디스플레이 주식회사 | 액정 조성물 및 이를 포함하는 액정 표시 장치 |
| WO2018026656A1 (en) * | 2016-08-01 | 2018-02-08 | University Of Pittsburgh -Of The Commonwealth System Of Higher Education | Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles |
| AU2018227811A1 (en) * | 2017-03-02 | 2019-09-19 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
| TWI795510B (zh) * | 2018-01-17 | 2023-03-11 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | PI4KIIIβ抑制劑 |
| WO2021079984A1 (ja) * | 2019-10-25 | 2021-04-29 | 大日本住友製薬株式会社 | 新規置換縮環型化合物 |
| CN111026203B (zh) * | 2019-12-02 | 2021-01-26 | 宁波德晶元科技有限公司 | 一种适用于真空热水壶的加热控制方法与系统 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| WO2001002424A2 (en) * | 1999-07-07 | 2001-01-11 | Du Pont Pharmaceuticals Company | Peptide boronic acid inhibitors of hepatitis c virus protease |
| CA2435146C (en) | 2001-01-25 | 2011-03-29 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Formulation of boronic acid compounds |
| UA79834C2 (en) | 2002-11-01 | 2007-07-25 | Viropharma Inc | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
| WO2008051244A2 (en) | 2005-12-01 | 2008-05-02 | Wyeth | Anthranilic acid derivatives useful in treating infection with hepatitis c virus |
| ES2542342T3 (es) | 2006-02-16 | 2015-08-04 | Anacor Pharmaceuticals, Inc. | Pequeñas moléculas que contienen boro como agentes antiinflamatorios |
| WO2007131072A2 (en) * | 2006-05-02 | 2007-11-15 | Anacor Pharmaceuticals, Inc. | Hydrolytically-resistant boron-containing therapeutics and methods of use |
| US20070286822A1 (en) | 2006-06-12 | 2007-12-13 | Anacor Pharmaceuticals Inc. | Compounds for the Treatment of Periodontal Disease |
| ES2569660T3 (es) * | 2007-06-08 | 2016-05-12 | Mannkind Corporation | Inhibidores de la IRE-1alfa |
| GB0719366D0 (en) * | 2007-10-03 | 2007-11-14 | Smithkline Beecham Corp | Compounds |
| RU2010137635A (ru) * | 2008-02-14 | 2012-03-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Гетероциклические антивирусные соединения |
| EP2187893A4 (en) | 2008-03-06 | 2012-02-22 | Anacor Pharmaceuticals Inc | SMALL BORON-CONTAINING MOLECULES AS ANTI-INFLAMMATORY AGENTS |
| WO2009137500A1 (en) * | 2008-05-05 | 2009-11-12 | Wyeth | 6-substituted benzofuran compounds to treat infection with hepatitis c virus |
| WO2009137493A1 (en) | 2008-05-05 | 2009-11-12 | Wyeth | 2-substituted benzofuran compounds to treat infection with hepatitis c virus |
| TW201008933A (en) | 2008-08-29 | 2010-03-01 | Hutchison Medipharma Entpr Ltd | Pyrimidine compounds |
| WO2010027975A1 (en) | 2008-09-04 | 2010-03-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| WO2011050284A1 (en) * | 2009-10-23 | 2011-04-28 | Glaxosmithkline Llc | Pyrazolylpyridine antiviral agents |
| AR080185A1 (es) | 2010-02-19 | 2012-03-21 | Glaxo Group Ltd | Derivados de acido boronico y benzofurano, composiciones farmaceuticas que los contienen,y uso de los mismos en el tratamiento y/o prevencion de infecciones virales, en particular por el virus de hepatitis c(hcv). |
| WO2011106986A1 (en) | 2010-03-02 | 2011-09-09 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus ns5b polymerase |
| TW201136919A (en) | 2010-03-02 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | Inhibitors of hepatitis C virus NS5B polymerase |
| WO2011106929A1 (en) | 2010-03-02 | 2011-09-09 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus ns5b polymerase |
| TW201221131A (en) * | 2010-11-18 | 2012-06-01 | Glaxo Group Ltd | Compounds |
| AU2011329486A1 (en) | 2010-11-18 | 2013-04-18 | Glaxo Group Limited | Compounds |
| WO2013025975A1 (en) * | 2011-08-17 | 2013-02-21 | Glaxosmithkline Llc | Combination treatments for hepatitis c |
| CN103929965B (zh) * | 2011-08-17 | 2016-08-17 | 葛兰素史克有限责任公司 | 治疗方法 |
| HUE030300T2 (en) | 2011-08-19 | 2017-04-28 | Glaxo Group Ltd | Benzofuran compounds for the treatment of hepatitis c virus infections |
-
2012
- 2012-08-10 HU HUE12826498A patent/HUE030300T2/en unknown
- 2012-08-10 EP EP16195408.6A patent/EP3199531A1/en not_active Withdrawn
- 2012-08-10 CN CN201280040219.3A patent/CN103732065B/zh not_active Expired - Fee Related
- 2012-08-10 AU AU2012299295A patent/AU2012299295B2/en not_active Ceased
- 2012-08-10 SI SI201230826A patent/SI2744332T1/sl unknown
- 2012-08-10 PH PH1/2014/500385A patent/PH12014500385A1/en unknown
- 2012-08-10 KR KR1020147007196A patent/KR101913800B1/ko not_active Expired - Fee Related
- 2012-08-10 IN IN572CHN2014 patent/IN2014CN00572A/en unknown
- 2012-08-10 CA CA2844086A patent/CA2844086A1/en not_active Abandoned
- 2012-08-10 WO PCT/US2012/050268 patent/WO2013028371A1/en active Application Filing
- 2012-08-10 EP EP12826498.3A patent/EP2744332B1/en active Active
- 2012-08-10 PE PE2014000197A patent/PE20141201A1/es not_active Application Discontinuation
- 2012-08-10 BR BR112014002845A patent/BR112014002845A2/pt not_active Application Discontinuation
- 2012-08-10 MX MX2014001989A patent/MX354676B/es active IP Right Grant
- 2012-08-10 HR HRP20161743TT patent/HRP20161743T1/hr unknown
- 2012-08-10 SG SG10201606883QA patent/SG10201606883QA/en unknown
- 2012-08-10 US US13/885,500 patent/US8927593B2/en not_active Expired - Fee Related
- 2012-08-10 DK DK12826498.3T patent/DK2744332T3/en active
- 2012-08-10 LT LTEP12826498.3T patent/LT2744332T/lt unknown
- 2012-08-10 EA EA201490213A patent/EA032841B1/ru not_active IP Right Cessation
- 2012-08-10 ME MEP-2016-287A patent/ME02588B/me unknown
- 2012-08-10 RS RS20161131A patent/RS55462B1/sr unknown
- 2012-08-10 JP JP2014526090A patent/JP6367712B2/ja not_active Expired - Fee Related
- 2012-08-10 ES ES12826498.3T patent/ES2611731T3/es active Active
- 2012-08-10 SM SM20170028T patent/SMT201700028T1/it unknown
- 2012-08-10 PL PL12826498T patent/PL2744332T3/pl unknown
- 2012-08-10 PT PT128264983T patent/PT2744332T/pt unknown
- 2012-08-16 AR ARP120103008A patent/AR087563A1/es unknown
- 2012-08-16 JO JOP/2012/0233A patent/JO3281B1/ar active
- 2012-08-17 TW TW101130017A patent/TWI538915B/zh not_active IP Right Cessation
- 2012-08-17 UY UY0001034274A patent/UY34274A/es not_active Application Discontinuation
-
2014
- 2014-01-16 IL IL230487A patent/IL230487B/en not_active IP Right Cessation
- 2014-01-23 CO CO14013113A patent/CO6862153A2/es active IP Right Grant
- 2014-02-10 ZA ZA201401020A patent/ZA201401020B/en unknown
- 2014-02-17 CL CL2014000393A patent/CL2014000393A1/es unknown
- 2014-02-18 CR CR20140078A patent/CR20140078A/es unknown
- 2014-02-19 DO DO2014000034A patent/DOP2014000034A/es unknown
- 2014-03-13 MA MA36832A patent/MA35443B1/fr unknown
- 2014-11-20 US US14/548,524 patent/US9682999B2/en not_active Expired - Fee Related
-
2016
- 2016-12-22 JP JP2016249387A patent/JP2017125010A/ja active Pending
- 2016-12-27 CY CY20161101345T patent/CY1118399T1/el unknown
-
2017
- 2017-01-18 SM SM201700028T patent/SMT201700028B/it unknown
- 2017-02-03 CL CL2017000293A patent/CL2017000293A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN00572A (enEXAMPLES) | ||
| MY170941A (en) | Pyrimidine derivatives for the treatment of viral infections | |
| IN2014MN02652A (enEXAMPLES) | ||
| IN2014MN02658A (enEXAMPLES) | ||
| IN2014MN02657A (enEXAMPLES) | ||
| IN2015MN00478A (enEXAMPLES) | ||
| IN2015DN01156A (enEXAMPLES) | ||
| IN2014MN00862A (enEXAMPLES) | ||
| MX375789B (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de hepatitis b. | |
| PH12015500724B1 (en) | 1, 2, 4-triazine derivatives for the treatment of viral infections | |
| MX2015011193A (es) | Compuestos antivirales. | |
| WO2013106689A8 (en) | Hcv ns3 protease inhibitors | |
| WO2011160024A3 (en) | Compounds useful as antiviral agents, compositions, and methods of use | |
| PH12014502551B1 (en) | Oligonucleotide chelate complex-polypeptide compositions and methods | |
| BR112014015582A8 (pt) | compostos antivirais | |
| MX2015011198A (es) | Compuestos antivirales. | |
| MX2015010790A (es) | Derivados de anilina sustituidos con n-heteroarilo como antivirales de vhc. | |
| IN2015DN02109A (enEXAMPLES) | ||
| MX2015010892A (es) | Compuestos antivirales. | |
| MX2015011125A (es) | Compuestos antivirales. | |
| MX2015011126A (es) | Compuestos antivirales. | |
| CU20140133A7 (es) | Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido | |
| UA113722C2 (uk) | Фармацевтична композиція |